Abstract
The most frequent type of primary liver cancer is hepatocellular carcinoma (HCC). Although HCC is not the most frequent cancer, it is characterized by high mortality – the 5-year survival rate is 6,9%. In recent decades there was only one molecule available in treatment (sorafenib). However, in the past few years there have been advances in treatment. Nowadays, new generation tyrosine kinase inhibitors, check point inhibitors and anti-angiogenesis drugs are available. All those studies were analyzed outcome in context of monotherapy or combined therapies. In this review we made an attempt to compare results from different studies. Even though, many studies are undergoing final stages of clinical trials, it seems that combined therapies should be the next step in treatment advances.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
